This study evaluates the association between antivirals (Molnupiravir and Nirmatrelvir-
Ritonavir) and all-cause and respiratory mortality and organ dysfunction among high-risk …

Introduction Molnupiravir (MOV) is an oral antiviral for the treatment of individuals with mild-
to-moderate COVID-19 and at high risk of progression to severe disease. Our objective was …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Introduction Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …

Objectives Real-world data on continued effectiveness of nirmatrelvir/ritonavir against
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …

Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe
Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data …

Background The oral antiviral molnupiravir is moderately effective in high-risk, unvaccinated
non-hospitalized patients infected with early variants of SARS-CoV-2. Data regarding the …

Besides the significant benefits of vaccination against COVID-19, the risk of severe disease
and death from COVID-19 among highly vulnerable populations remains of concern …

Antiviral therapeutics for COVID-19 in nonhospitalized patients prevent progression to
severe illness, hospitalization, and death. Despite their proven benefit, utilization of these …